![Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea](/docs/US/2023-01-03/US11541058B2/abs.jpg.600x600.jpg)
- Patent Title: Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
-
Application No.: US16641045Application Date: 2018-08-20
-
Publication No.: US11541058B2Publication Date: 2023-01-03
- Inventor: James Joseph Hussey , Andrew Gilbert Bright
- Applicant: PFIZER INC.
- Applicant Address: US NY New York
- Assignee: PFIZER INC.
- Current Assignee: PFIZER INC.
- Current Assignee Address: US NY New York
- Agency: Nelson Mullins Riley & Scarborough LLP
- Agent Jane E. Remillard, Esq.
- International Application: PCT/IB2018/056281 WO 20180820
- International Announcement: WO2019/038657 WO 20190228
- Main IPC: A61K31/5377
- IPC: A61K31/5377 ; A61K9/08 ; A61K9/19 ; A61K47/40 ; A61K47/20 ; A61K9/00 ; A61K47/26
![Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea](/abs-image/US/2023/01/03/US11541058B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
Public/Granted literature
Information query
IPC分类:
